Enzovax 20 dose

Target species Susceptible female breeding sheep. Indications for use For the active immunisation of susceptible female breeding sheep to reduce abortion caused by Chlamydophila abortus infection. Challenge studies have demonstrated that protection against Enzootic abortion and excretion of Chlamydophila abortus post-challenge is undiminished for at least three years post vaccination with Enzovax. Field studies in endemically infected flocks maintaining a policy of vaccinating incoming ewes with Enzovax indicate that enzootic abortion levels remain very low in ewes vaccinated 4 years previously. Contraindications Do not vaccinate pregnant animals. Do not vaccinate animals less than 4 weeks before mating. Do not vaccinate animals which are being treated with antibiotics, particularly tetracyclines. Special warnings for each target species Chlamydophila abortus is only one of the causes of abortion in sheep. If the abortion rate remains unchanged in flocks which have been vaccinated with Enzovax it is recommended that veterinary advice is sought. The epidemiology of abortion due to Chlamydophila abortus in ewes involves a long incubation period. Ewes that abort in any lambing season have usually been infected at the previous lambing. Field trial data indicate that vaccinating incubating ewes will reduce the incidence of abortion, but a proportion can still go on to abort. Care should be taken in handling such abortions as susceptible humans may be at risk of infection. A good immune response is reliant on the reaction of an immunogenic agent and a fully competent immune system. Immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration. Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress. Special precautions for use None. Operator warnings Enzovax should not be handled by pregnant women or women of child bearing age as the vaccine may cause abortion. Enzovax should not be handled by persons who are immuno-deficient (e.g. AIDS sufferers, persons undergoing chemotherapy or taking immuno-suppressive drugs). If in any doubt, you should consult your GP. To the user: Operators should wear gloves when handling the vaccine. Care should be taken to avoid self-injection, but if this occurs, immediate medical advice should be sought and the doctor informed that self-injection with a living chlamydophila vaccine has occurred. To the physician: Tetracycline therapy is the current recognised treatment for infection with Chlamydophila abortus in humans. Adverse reactions A transient temperature rise may be observed after vaccination (average of up to 1.5